Safety and Tolerability Study of PF-06835375 in Subjects with Seropositive Systemic Lupus
Erythematosus or Rheumatoid Arthritis. [A Phase 1, Randomized, Multi-Center, Double-Blind,
Sponsor Open, Placebo-Controlled, Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06835375 in Subjects with Seropositive Systemic Lupus Erythematosus or Rheumatoid Arthritis.